Duodenal Ulcer Therapy, “Acid Rebound,” and Early Relapse
It is generally accepted that duodenal ulcers (DU) recur within a year in 75-90% of patients following healing with an HZ-receptor antagonist (H2RA). Relapse rates following initial treatment with colloidal bismuth agents are appreciably, and often significantly, lower than those following initial treatment with an H2RA, and a similar short-term advantage has been reported in most 3- to 6-month follow-up studies in patients healed initially with sucralfate. The reason for the trend toward lower relapse rates following ulcer healing with mucosal protective agents is not clear. Attention has been drawn to differences in the quality of ulcer healing following treatment with an H2RA and the mucosal protective agents, and the antimicrobial effect of colloidal bismuth agents against H. pylori-and the possible effect of sucralfate on these organisms is clearly pertinent. A third possibility relates to the concept of increased parietal cell sensitivity following treatment with an H2RA. This review will focus on acid secretory changes following DU healing with sucralfate and H2RAs, and an attempt will be made to link these with the liability to early relapse.
KeywordsDuodenal Ulcer Acid Secretion Ulcer Healing Early Relapse Duodenal Ulcer Healing
Unable to display preview. Download preview PDF.
- 5.Nwokolo CU, Smith JTL, Pounder RE: Rebound intragastric hyperacidity occurs following dosing with cimetidine, nizatidine and famotidine. Gastroenterology 96:A369, 1989.Google Scholar
- 6.Prewett EJ, Hudson M, Nwokolo CU, et al: Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 100:873–877, 1991. Studies in control subjects showing acid rebound following treatment with various H2-receptor blockers.PubMedGoogle Scholar
- 8.Johnston DA, Marks IN, Young GO, et al: Maintenance treatment with ranitidine and sucralfate does not affect acid secretory responses. S Afr Med J 78:A353, 1990.Google Scholar
- 11.Wilder-Smith DH, Halter F, Merke HS: Tolerance and rebound hyperacidity in DU patients. Gut 31:A600, 1990. Studies in patients with duodenal ulcer in remission using different parameters of acid secretion and showing conflicting results following treatment with variable doses of H2RAs.Google Scholar
- 17.Johnston DA, Marks IN: Short-term relapse rates after duodenal ulcer healing. S Afr J Cont Med 8:999–1002, 1990. Studies examining the effect of H2RAs in patients with active duodenal ulcer using different parameters of acid secretion. Acid rebound was noted only in the study in which nocturnal acid secretion was measured.Google Scholar
- 19.Yanaka A, Muto H: Increased parietal cell responsiveness to tetragastrin in patients with recurrent duodenal ulcer. Dig Dis Sci 33(11):1459–1465, 1988. Studies documenting the relationship between persistent elevation of parietal cell sensitivity on duodenal cell healing and early relapse.PubMedCrossRefGoogle Scholar